Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pharmacogenomics of tamoxifen in a nutshell-and who broke the nutcracker?

Literature DB >> 20871698

Pharmacogenomics of tamoxifen in a nutshell-and who broke the nutcracker?

Frankie Ann Holmes, Jeffrey D Liticker.

Abstract

Entities: Chemical

Year: 2005 PMID： 20871698 PMCID： PMC2794560 DOI： 10.1200/JOP.2005.1.4.155

Source DB: PubMed Journal: J Oncol Pract ISSN： 1554-7477 Impact factor: 3.840

× No keyword cloud information.

12 in total

Review 1. Drug-induced prolongation of the QT interval.

Authors: Dan M Roden
Journal: N Engl J Med Date: 2004-03-04 Impact factor: 91.245

2. Risk factors as reflected by an intensive drug monitoring system.

Authors: T Jacubeit; D Drisch; E Weber
Journal: Agents Actions Suppl Date: 1990

3. Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer.

Authors: William P Petros; Penelope J Hopkins; Susan Spruill; Gloria Broadwater; James J Vredenburgh; O Michael Colvin; William P Peters; Roy B Jones; Jeff Hall; Jeffrey R Marks
Journal: J Clin Oncol Date: 2005-08-08 Impact factor: 44.544

4. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.

Authors: Yan Jin; Zeruesenay Desta; Vered Stearns; Bryan Ward; Herbert Ho; Kyung-Hoon Lee; Todd Skaar; Anna Maria Storniolo; Lang Li; Adjei Araba; Rebecca Blanchard; Anne Nguyen; Lynda Ullmer; Jill Hayden; Suzanne Lemler; Richard M Weinshilboum; James M Rae; Daniel F Hayes; David A Flockhart
Journal: J Natl Cancer Inst Date: 2005-01-05 Impact factor: 13.506

Review 5. Molecular portraits of breast cancer: tumour subtypes as distinct disease entities.

Authors: Therese Sørlie
Journal: Eur J Cancer Date: 2004-12 Impact factor: 9.162

6. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.

Authors: T Shimada; H Yamazaki; M Mimura; Y Inui; F P Guengerich
Journal: J Pharmacol Exp Ther Date: 1994-07 Impact factor: 4.030

7. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.

Authors: Vered Stearns; Michael D Johnson; James M Rae; Alan Morocho; Antonella Novielli; Pankaj Bhargava; Daniel F Hayes; Zeruesenay Desta; David A Flockhart
Journal: J Natl Cancer Inst Date: 2003-12-03 Impact factor: 13.506

8. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer.

Authors: M Ayers; W F Symmans; J Stec; A I Damokosh; E Clark; K Hess; M Lecocke; J Metivier; D Booser; N Ibrahim; V Valero; M Royce; B Arun; G Whitman; J Ross; N Sneige; G N Hortobagyi; L Pusztai
Journal: J Clin Oncol Date: 2004-05-10 Impact factor: 44.544

Pharmacogenomics of tamoxifen in a nutshell-and who broke the nutcracker?

Review 1. Drug-induced prolongation of the QT interval.

2. Risk factors as reflected by an intensive drug monitoring system.

3. Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer.

4. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.

Review 5. Molecular portraits of breast cancer: tumour subtypes as distinct disease entities.

6. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.

7. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.

8. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer.

9. Torsades de pointes occurring in association with terfenadine use.

10. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer.

1. Pharmacogenomics in the clinic: new questions about tamoxifen.

2. Influence of a three-dimensional, microarray environment on human cell culture in drug screening systems.

Review 3. Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations.

4. Tamoxifen and Antidepressant Drug Interaction in a Cohort of 16,887 Breast Cancer Survivors.

5. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.

6. Targeting Estrogen Receptor-Positive Breast Microtumors with Endoxifen-Conjugated, Hypoxia-Sensitive Polymersomes.